Panavance Therapeutics Inc.

📍 Berwyn, United States🗓 Founded 2021👥 9 employees💰 Last funded Oct 2021
Pharmaceutical Manufacturing🌐 panavance.com
Website LinkedIn
Panavance Therapeutics Inc. is a US, clinical-stage pharmaceutical company established in 2021 by the Swiss-based Avensis Pharma AG, a subsidiary of Ed. Geistlich Söhne AG für Chemische Industrie. Panavance is focused on advancing the development of GP-2250, a novel oncology therapeutic intended to improve outcomes and quality of life for patients with cancer. With its highly capable team and strong academic and industry partnerships, Panavance is pursuing a rigorous program to bring GP-2250 to patients around the world.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2021
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Switzerland
1
Frequently asked questions
Who invested in Panavance Therapeutics Inc.?
Panavance Therapeutics Inc. has 1 investors on record on gritt.io, including 1 early-stage backers.
When did Panavance Therapeutics Inc. last raise funding?
The most recent investment in Panavance Therapeutics Inc. recorded on gritt.io was in October 2021.
When was Panavance Therapeutics Inc. founded?
Panavance Therapeutics Inc. was founded in 2021.
What industry is Panavance Therapeutics Inc. in?
Panavance Therapeutics Inc. operates in Pharmaceutical Manufacturing. Find similar Pharmaceutical Manufacturing investors on gritt.io.
Where is Panavance Therapeutics Inc. based?
Panavance Therapeutics Inc. is headquartered in Berwyn, United States.